Literature DB >> 36262075

Direct Oral Anti-Coagulants Continue to Bud into Gynecological Cancer-Thrombosis Prevention.

Alfonso J Tafur1, Elena Diaz Moore2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36262075      PMCID： PMC9585564          DOI： 10.1177/10760296221133792

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN： 1076-0296            Impact factor:   3.512


× No keyword cloud information.
  10 in total

1.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Authors:  Helen K Chew; Theodore Wun; Danielle Harvey; Hong Zhou; Richard H White
Journal:  Arch Intern Med       Date:  2006-02-27

Review 2.  Venous thromboembolism prophylaxis using the Caprini score.

Authors:  Iva Golemi; Juan Pablo Salazar Adum; Alfonso Tafur; Joseph Caprini
Journal:  Dis Mon       Date:  2019-01-09       Impact factor: 3.800

3.  Validation of a venous thromboembolism risk assessment model in gynecologic oncology.

Authors:  William Stroud; Jenny M Whitworth; Margaret Miklic; Kellie E Schneider; Michael A Finan; Jennifer Scalici; Eddie Reed; Lisa Bazzett-Matabele; J Michael Straughn; Rodney P Rocconi
Journal:  Gynecol Oncol       Date:  2014-05-04       Impact factor: 5.482

4.  Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.

Authors:  Gregory M Gressel; Jenna Z Marcus; Mary M Mullen; Abdulrahman K Sinno
Journal:  Gynecol Oncol       Date:  2020-11-28       Impact factor: 5.482

5.  Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?

Authors:  Brenna E Swift; Azusa Maeda; Genevieve Bouchard-Fortier
Journal:  Gynecol Oncol       Date:  2021-12-16       Impact factor: 5.482

Review 6.  A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology.

Authors:  Federico Romano; Giovanni Di Lorenzo; Guglielmo Stabile; Mariateresa Mirandola; Stefano Restaino; Patrizia Ianniello; Giuseppe Mirenda; Giuseppe Ricci
Journal:  Cancers (Basel)       Date:  2022-05-15       Impact factor: 6.575

7.  Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.

Authors:  Cecilia Becattini; Ugo Pace; Felice Pirozzi; Annibale Donini; Giampiero Avruscio; Fabio Rondelli; Michela Boncompagni; Damiano Chiari; Marco De Prizio; Adriana Visonà; Raffaele De Luca; Francesco Guerra; Andrea Muratore; Giuseppe Portale; Marco Milone; Giampaolo Castagnoli; Marc Righini; Jacopo Martellucci; Roberto Persiani; Stefania Frasson; Francesco Dentali; Paolo Delrio; Mauro Campanini; Gualberto Gussoni; Maria Cristina Vedovati; Giancarlo Agnelli
Journal:  Blood       Date:  2022-08-25       Impact factor: 25.476

8.  Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study.

Authors:  Sam Schulman; Vanessa Carlson; Pablo E Serrano; Niv Sne; Kamyar Kahnamoui; Siraj Mithoowani; Rick Ikesaka; Peter L Gross
Journal:  J Surg Oncol       Date:  2022-04-01       Impact factor: 2.885

9.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.

Authors:  Saketh R Guntupalli; Alyse Brennecke; Kian Behbakht; Anna Tayebnejad; Christopher A Breed; Lisa Marie Babayan; Georgina Cheng; Amin A Ramzan; Lindsay J Wheeler; Bradley R Corr; Carolyn Lefkowits; Jeanelle Sheeder; Koji Matsuo; Dina Flink
Journal:  JAMA Netw Open       Date:  2020-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.